AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Glutamate receptor ionotropic, kainate 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q13002

UPID:

GRIK2_HUMAN

Alternative names:

Excitatory amino acid receptor 4; Glutamate receptor 6

Alternative UPACC:

Q13002; A6NMY9; B5MCV0; D7RWZ3; D7RWZ4; D7RWZ5; D7RWZ6; D7RWZ7; Q8WWS1; Q96KS6; Q96KS7; Q96KS8

Background:

Glutamate receptor ionotropic, kainate 2, also known as Excitatory amino acid receptor 4 or Glutamate receptor 6, plays a pivotal role in the central nervous system as an ionotropic glutamate receptor. It transforms chemical signals into electrical impulses through the binding of L-glutamate, facilitating rapid communication between neurons. Additionally, it exhibits thermoreceptor activity, sensitive to cold temperatures, particularly in dorsal root ganglion neurons.

Therapeutic significance:

This protein is implicated in Intellectual developmental disorder, autosomal recessive 6, and Neurodevelopmental disorder with impaired language and ataxia, both characterized by developmental delays and intellectual challenges. Understanding the role of Glutamate receptor ionotropic, kainate 2 could open doors to potential therapeutic strategies for these neurological conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.